Development of Indices Predicting Response to Pre-operative Chemotherapy in Osteosarcoma Patients
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00686738|
Recruitment Status : Completed
First Posted : May 30, 2008
Last Update Posted : March 23, 2016
|Condition or disease|
|Study Type :||Observational|
|Actual Enrollment :||20 participants|
|Official Title:||Validity Verification of Indices Utilizing TGF-b1, NF-kB, PET/CT, and MRS Predicting Response to Neoadjuvant Chemotherapy in Osteosarcoma Patients|
|Study Start Date :||February 2007|
|Actual Primary Completion Date :||November 2012|
|Actual Study Completion Date :||December 2015|
Study group will be made up of patients hospitalized to National Cancer Center, Korea, aged between 5 and 40 years, and diagnosed with high grade osteosarcoma by histological exam.
In this group, TGF-b1 measurement, PET/CT and MRS examination at diagnosis, after 1st cycle chemotherapy, and 2nd or 3rd chemotherapy (just before surgery) will be made.
In addition, evaluation of NF-kB expression status in tumor specimens at diagnostic biopsy and tumor removing surgery will be done.
The results of above studies will be correlated with the necrosis fractions of the tumor tissues removed by surgery.
- histopathologic necrosis fractions of surgically removed tumor specimen [ Time Frame: 12-17 weeks after starting chemotherapy ]
Biospecimen Retention: Samples Without DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00686738
|Korea, Republic of|
|National Cancer Center|
|Goyang-si, Gyeonggi, Korea, Republic of|
|Principal Investigator:||Byung-Kiu Park, M.D., Ph.D.||Pediatric Oncology Branch, National Cancer Center, Korea|